Press Releases

Receive E-mail Alerts
18 November 2019 at 7:23 AM EST
Summary ToggleProQR to Present at Upcoming Scientific Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Company management
13 November 2019 at 7:00 AM EST
Summary ToggleProQR to Present at Upcoming Investor Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Company management
6 November 2019 at 7:00 AM EST
Summary ToggleProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 QR-1123 Investigational New Drug application active for autosomal dominant retinitis pigmentosa €49.3 million net
18 October 2019 at 8:20 AM EDT
Summary ToggleProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previously
15 October 2019 at 11:17 PM EDT
Summary ToggleProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the pricing of its
15 October 2019 at 4:13 PM EDT
Summary ToggleProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to
15 October 2019 at 4:08 PM EDT
Summary ToggleProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease
10 October 2019 at 6:00 AM EDT
Summary ToggleProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
  Reported rapid, significant and durable improvements in vision at twelve months   Concordant improvement in key secondary outcome measures   The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile   Strengthens confidence in the ongoing Phase 2/3
7 October 2019 at 7:00 AM EDT
Summary ToggleProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss
30 September 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at Two Investor Conferences in October
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company
9 September 2019 at 7:00 AM EDT
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast
12 August 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.
7 August 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Financial Results for the Second Quarter of 2019
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for
29 July 2019 at 7:00 AM EDT
Summary ToggleEuropean Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
Access based on positive interim analysis of clinical data as well as preclinical data to date  PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval ProQR believes that the EU will represent an important market
2 July 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
LEIDEN, Netherlands and CAMBRIDGE, Mass. , July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced an upcoming presentation
3 June 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the JMP Securities Life Sciences Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company
15 May 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the RBC Capital Markets Healthcare Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
8 May 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Financial Results for the First Quarter of 2019
LEIDEN, Netherlands & CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the
22 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at Three Scientific Conferences in April
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filius , Chief
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Annual General
15 April 2019 at 7:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
LEIDEN, The Netherlands and CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient
1 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the H.C. Wainwright Global Life Sciences Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
26 March 2019 at 4:01 PM EDT
Summary ToggleProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out
11 March 2019 at 4:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed
5 March 2019 at 7:00 AM EST
Summary ToggleProQR to Present at Cowen Health Care Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the management will
27 February 2019 at 7:00 AM EST
Summary ToggleProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
LEIDEN, The Netherlands & CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results
29 January 2019 at 8:30 AM EST
Summary ToggleProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and
7 January 2019 at 7:00 AM EST
Summary ToggleProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached
3 January 2019 at 7:00 AM EST
Summary ToggleProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY .
2 January 2019 at 7:00 AM EST
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track